# Avonex®: Safety, Blood Levels and Effects

> **NCT01863069** · PHASE1 · COMPLETED · sponsor: **Trio Medicines Ltd.** · enrollment: 77 (actual)

## Conditions studied

- Multiple Sclerosis (MS)

## Interventions

- **DRUG:** Interferon beta 1a
- **DRUG:** (IM) AVONEX®

## Key facts

- **NCT ID:** NCT01863069
- **Lead sponsor:** Trio Medicines Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-01
- **Primary completion:** 2001-10
- **Final completion:** 2001-10
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2013-05-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01863069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01863069, "Avonex®: Safety, Blood Levels and Effects". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01863069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*